Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 23 | 2020 | 670 | 3.390 |
Why?
|
| Hallucinations | 9 | 2023 | 42 | 1.850 |
Why?
|
| Emotions | 2 | 2015 | 72 | 0.520 |
Why?
|
| Visual Pathways | 2 | 2014 | 2 | 0.510 |
Why?
|
| Amygdala | 1 | 2015 | 39 | 0.490 |
Why?
|
| Blindness | 1 | 2014 | 8 | 0.450 |
Why?
|
| Contrast Sensitivity | 3 | 2002 | 6 | 0.400 |
Why?
|
| Brain | 3 | 2023 | 1649 | 0.390 |
Why?
|
| Humans | 28 | 2023 | 27074 | 0.360 |
Why?
|
| Placebo Effect | 1 | 2008 | 12 | 0.300 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2008 | 2 | 0.300 |
Why?
|
| Placebos | 1 | 2008 | 65 | 0.300 |
Why?
|
| Tauopathies | 1 | 2008 | 20 | 0.300 |
Why?
|
| Depressive Disorder | 1 | 2008 | 177 | 0.280 |
Why?
|
| Fetal Tissue Transplantation | 2 | 2000 | 22 | 0.270 |
Why?
|
| Dystonia | 3 | 1997 | 12 | 0.270 |
Why?
|
| Head | 1 | 2006 | 23 | 0.250 |
Why?
|
| Multiple System Atrophy | 1 | 2006 | 32 | 0.250 |
Why?
|
| Visual Perception | 2 | 2005 | 30 | 0.250 |
Why?
|
| Color Vision Defects | 2 | 2002 | 3 | 0.240 |
Why?
|
| Myositis | 1 | 2006 | 33 | 0.240 |
Why?
|
| Age of Onset | 2 | 2003 | 94 | 0.240 |
Why?
|
| Pain | 1 | 2008 | 413 | 0.240 |
Why?
|
| Brain Chemistry | 1 | 2005 | 43 | 0.230 |
Why?
|
| Cerebral Cortex | 2 | 2020 | 155 | 0.220 |
Why?
|
| Sick Role | 1 | 2003 | 15 | 0.210 |
Why?
|
| Vision Disorders | 2 | 2005 | 20 | 0.210 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 34 | 0.210 |
Why?
|
| Models, Biological | 1 | 2005 | 322 | 0.200 |
Why?
|
| Space Perception | 1 | 2002 | 22 | 0.200 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 175 | 0.200 |
Why?
|
| Levodopa | 4 | 2009 | 34 | 0.190 |
Why?
|
| Aged | 12 | 2008 | 8997 | 0.190 |
Why?
|
| Middle Aged | 11 | 2008 | 8923 | 0.190 |
Why?
|
| Subthalamic Nucleus | 1 | 2000 | 19 | 0.170 |
Why?
|
| Electric Stimulation Therapy | 1 | 2000 | 41 | 0.170 |
Why?
|
| Axons | 1 | 2020 | 28 | 0.170 |
Why?
|
| Adrenal Glands | 1 | 2000 | 10 | 0.170 |
Why?
|
| Mitochondria | 1 | 2020 | 67 | 0.170 |
Why?
|
| Corpus Striatum | 1 | 2000 | 65 | 0.160 |
Why?
|
| Movement Disorders | 2 | 1998 | 66 | 0.160 |
Why?
|
| Huntington Disease | 1 | 2000 | 48 | 0.160 |
Why?
|
| Botulinum Toxins | 2 | 1997 | 8 | 0.160 |
Why?
|
| Sleep Wake Disorders | 3 | 2009 | 123 | 0.160 |
Why?
|
| Biological Evolution | 1 | 2019 | 9 | 0.160 |
Why?
|
| Substantia Nigra | 1 | 2000 | 120 | 0.160 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1998 | 4 | 0.150 |
Why?
|
| Color Perception | 1 | 1998 | 5 | 0.150 |
Why?
|
| Male | 12 | 2008 | 14772 | 0.150 |
Why?
|
| Mental Disorders | 1 | 2000 | 141 | 0.150 |
Why?
|
| Muscle Relaxants, Central | 1 | 1997 | 3 | 0.140 |
Why?
|
| Baclofen | 1 | 1997 | 3 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 1998 | 18 | 0.140 |
Why?
|
| Neurons | 1 | 2020 | 339 | 0.140 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 1996 | 1 | 0.130 |
Why?
|
| Genes | 1 | 1996 | 7 | 0.130 |
Why?
|
| Globus Pallidus | 1 | 1996 | 10 | 0.130 |
Why?
|
| Genetic Variation | 1 | 1996 | 96 | 0.130 |
Why?
|
| Phylogeny | 1 | 2015 | 51 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2006 | 1792 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 1997 | 117 | 0.120 |
Why?
|
| Superior Colliculi | 1 | 2014 | 1 | 0.110 |
Why?
|
| Basal Ganglia | 2 | 2008 | 14 | 0.110 |
Why?
|
| Female | 9 | 2008 | 15213 | 0.100 |
Why?
|
| Adrenal Medulla | 1 | 1993 | 7 | 0.100 |
Why?
|
| Lewy Bodies | 1 | 2014 | 192 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 1112 | 0.100 |
Why?
|
| Thalamus | 1 | 1992 | 15 | 0.100 |
Why?
|
| Dopamine Agents | 1 | 1992 | 11 | 0.100 |
Why?
|
| Dopamine | 2 | 2008 | 82 | 0.100 |
Why?
|
| Risk Factors | 3 | 2005 | 2302 | 0.090 |
Why?
|
| Vision Tests | 2 | 2002 | 4 | 0.090 |
Why?
|
| Antiparkinson Agents | 2 | 2003 | 42 | 0.090 |
Why?
|
| Illusions | 1 | 2009 | 1 | 0.080 |
Why?
|
| Neurotransmitter Agents | 1 | 2009 | 16 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2009 | 14 | 0.080 |
Why?
|
| Disease Progression | 2 | 2003 | 673 | 0.080 |
Why?
|
| Antipsychotic Agents | 1 | 2009 | 55 | 0.080 |
Why?
|
| Opioid Peptides | 1 | 2008 | 10 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 39 | 0.080 |
Why?
|
| Cognition Disorders | 2 | 2009 | 985 | 0.080 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2008 | 21 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 87 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 3 | 0.060 |
Why?
|
| Electromyography | 1 | 2006 | 71 | 0.060 |
Why?
|
| Animals | 2 | 2009 | 3642 | 0.060 |
Why?
|
| Biopsy | 1 | 2006 | 201 | 0.060 |
Why?
|
| Reality Testing | 1 | 2003 | 2 | 0.050 |
Why?
|
| Dementia | 1 | 2008 | 560 | 0.050 |
Why?
|
| Adult | 3 | 2003 | 7831 | 0.050 |
Why?
|
| Self Care | 1 | 2003 | 89 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2006 | 383 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2003 | 270 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 683 | 0.050 |
Why?
|
| Logistic Models | 1 | 2003 | 395 | 0.050 |
Why?
|
| Social Support | 1 | 2003 | 196 | 0.050 |
Why?
|
| Prevalence | 1 | 2003 | 443 | 0.050 |
Why?
|
| Comorbidity | 1 | 2003 | 481 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2003 | 347 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2003 | 587 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2003 | 624 | 0.040 |
Why?
|
| Syndrome | 1 | 2000 | 76 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 879 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 4777 | 0.040 |
Why?
|
| Sleep, REM | 1 | 1998 | 15 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 1998 | 45 | 0.040 |
Why?
|
| Violence | 1 | 1998 | 39 | 0.040 |
Why?
|
| Botulinum Toxins, Type A | 1 | 1997 | 8 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1997 | 5 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 1997 | 23 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 161 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2002 | 1778 | 0.030 |
Why?
|
| Muscle Spasticity | 1 | 1997 | 5 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 333 | 0.030 |
Why?
|
| Motor Neurons | 1 | 1996 | 18 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 1996 | 38 | 0.030 |
Why?
|
| Models, Neurological | 1 | 1996 | 25 | 0.030 |
Why?
|
| Registries | 1 | 1996 | 189 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 1997 | 1368 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 1993 | 10 | 0.030 |
Why?
|
| Oxidopamine | 1 | 1993 | 10 | 0.030 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 1993 | 20 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 1993 | 14 | 0.030 |
Why?
|
| Lisuride | 1 | 1992 | 1 | 0.020 |
Why?
|
| Methylcellulose | 1 | 1992 | 2 | 0.020 |
Why?
|
| Pergolide | 1 | 1992 | 2 | 0.020 |
Why?
|
| Apomorphine | 1 | 1992 | 3 | 0.020 |
Why?
|
| Bromocriptine | 1 | 1992 | 4 | 0.020 |
Why?
|
| Lactose | 1 | 1992 | 3 | 0.020 |
Why?
|
| Receptors, Dopamine | 1 | 1992 | 8 | 0.020 |
Why?
|
| Oxazines | 1 | 1992 | 6 | 0.020 |
Why?
|
| Functional Laterality | 1 | 1992 | 59 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1992 | 260 | 0.020 |
Why?
|
| Tremor | 1 | 1992 | 104 | 0.020 |
Why?
|
| Parasympatholytics | 1 | 1990 | 3 | 0.020 |
Why?
|
| Dopamine Antagonists | 1 | 1990 | 5 | 0.020 |
Why?
|
| Neuromuscular Diseases | 1 | 1990 | 5 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1992 | 333 | 0.020 |
Why?
|
| Neurosurgery | 1 | 1990 | 30 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1990 | 348 | 0.020 |
Why?
|
| Time Factors | 1 | 1992 | 1433 | 0.020 |
Why?
|
| Caregivers | 1 | 1998 | 197 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1998 | 1144 | 0.010 |
Why?
|